Abstract
Filarial infections are characterized by immunopathological phenomena, that are responsible for the onset of often dramatic pathological outcomes, such as blindness (Onchocerca volvulus) and elephantiasis (W. bancrofti). In addition, the long-term survival (as long as 10 years) of these parasites in otherwise immunocompetent hosts indicates that these nematodes are capable of manipulating the host immune response. The ground-breaking discovery of the bacterial endosymbiont Wolbachia, which resides in most filarial nematodes causing disease, has led to increasing interest in the role it may play in immuno-modulation, pro-inflammatory pathology and other aspects of filarial infection. Indeed, Wolbachia has been shown to be responsible for exacerbating inflammation (as in river blindness), while at the same time blocking efficient elimination of parasites through the host immune response (Onchocerca ochengi). While studies aimed at identifying Wolbachia as a potential target for anti-filarial therapy are at the forefront of current research, understanding its role in the immunology of filarial infection is a fascinating field that has yet to uncover many secrets.
Keywords: Filarial nematodes, Wolbachia, symbiosis, reproductive parasite, PAMPs, immuno-modulation, pathology, pro-inflammatory, immune response, filariasis
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Wolbachia and Its Implications for the Immunopathology of Filariasis
Volume: 12 Issue: 1
Author(s): Claudio Genchi, Laura H. Kramer, Davide Sassera and Claudio Bandi
Affiliation:
Keywords: Filarial nematodes, Wolbachia, symbiosis, reproductive parasite, PAMPs, immuno-modulation, pathology, pro-inflammatory, immune response, filariasis
Abstract: Filarial infections are characterized by immunopathological phenomena, that are responsible for the onset of often dramatic pathological outcomes, such as blindness (Onchocerca volvulus) and elephantiasis (W. bancrofti). In addition, the long-term survival (as long as 10 years) of these parasites in otherwise immunocompetent hosts indicates that these nematodes are capable of manipulating the host immune response. The ground-breaking discovery of the bacterial endosymbiont Wolbachia, which resides in most filarial nematodes causing disease, has led to increasing interest in the role it may play in immuno-modulation, pro-inflammatory pathology and other aspects of filarial infection. Indeed, Wolbachia has been shown to be responsible for exacerbating inflammation (as in river blindness), while at the same time blocking efficient elimination of parasites through the host immune response (Onchocerca ochengi). While studies aimed at identifying Wolbachia as a potential target for anti-filarial therapy are at the forefront of current research, understanding its role in the immunology of filarial infection is a fascinating field that has yet to uncover many secrets.
Export Options
About this article
Cite this article as:
Genchi Claudio, H. Kramer Laura, Sassera Davide and Bandi Claudio, Wolbachia and Its Implications for the Immunopathology of Filariasis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (1) . https://dx.doi.org/10.2174/187153012799279108
DOI https://dx.doi.org/10.2174/187153012799279108 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Etiology of Hypertension in the Metabolic Syndrome Part One: An Introduction to the History, the Concept and the Models
Current Vascular Pharmacology Endless Pursuit: Evolution of Insulin Administration
Current Pharmaceutical Biotechnology Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel Vitreous Modulators for Pharmacologic Vitreolysis in the Treatment of Diabetic Retinopathy
Current Pharmaceutical Biotechnology Neuroimmunomodulation and Aging: A Role for Transferrin and the Hypothalamus/Thymus Axis
Current Aging Science Tissue Engineering for Post-Myocardial Infarction Ventricular Remodeling
Mini-Reviews in Medicinal Chemistry Lipids and Non-Cardiac Vascular Disease: A Lecture Overview
Current Vascular Pharmacology Exploring the Various Aspects of Brain-Derived Neurotropic Factor (BDNF) in Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets EDITORIAL [Hot Topic: Brazilian Natural Products - Part I (Guest Editor: Robert E. Smith)]
The Natural Products Journal Liraglutide-A Novel GLP-1 Analogue
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Editorial [Hot topic: Membrane Estrogen Receptors (Guest Editor: Paul J. Davis)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study
Current Alzheimer Research Mechanistic Insights Into Diabetes Mellitus and Oxidative Stress
Current Medicinal Chemistry Nanohybrids of Dendrimers and Carbon Nanotubes: A Benefaction or Forfeit in Drug Delivery?
Nanoscience & Nanotechnology-Asia Editorial (Thematic Issue: Global Trends in Nanotechnological Approaches for Various Health Issues – Volume II)
Current Drug Metabolism Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry Comparative Glycaemic Indices of a Four Herbal Combinatorial Formulation Administered On Wistar Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets An Integrated Computational Approach for Plant-Based Protein Tyrosine Phosphatase Non-Receptor Type 1 Inhibitors
Current Computer-Aided Drug Design Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Cardiovascular & Hematological Disorders-Drug Targets ADAM28 as a Target for Human Cancers
Current Pharmaceutical Design